In the PD-1 inhibitor plus apatinib group, the primary grade 3 adverse events were neutropenia (10.0%), thrombocytopenia (10.0%), and anemia (5.0%); in the apatinib group, the significant grade 3 adverse events were hypertension (8.0%), anemia (4.0%), and neutropenia (4.0%). This evidence concerns the gene PDCD1 and Hypertension.